The leukotriene receptor antagonist Montelukast can induce adverse skin reactions in asthmatic patients

Salvo, Eleonora Di; Casciaro, Marco; Gangemi, Sebastiano

doi:10.1016/j.pupt.2019.101875

Cited by 7 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several case studies show that prolonged use of montelukast resulted in the onset of cutaneous inflammatory disorders as the result of vasculitis onset associated with increased neutrophil and eosinophil recruitment. 98,99 Presentation of this type of adverse reactions is rare, and although the treatment period in our model was relatively short, we did not observe signs of vasculitis and increased granulocyte infiltration at the burn wound site in the montelukast-treated group. There is currently no clinical information on the effect of montelukast in wound healing in humans.…”

Section: Discussionmentioning

confidence: 62%

Montelukast, an Antagonist of Cysteinyl Leukotriene Signaling, Impairs Burn Wound Healing

Nguyen

Bagood

Wang

et al. 2022

Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

In the United States, over 30,000 patients are hospitalized annually because of burn injuries. 1 These injuries are often slow to heal, leading to lengthy hospitalization time, increased health care costs, and lower quality of life. Burnassociated impaired healing is linked to deregulated inflammation at the site of the injury driven by skin-resident and infiltrating peripheral immune cells. [2][3][4] Although certain inflammatory responses impair healing, 5-8 others promote tissue repair and reconstruction. [7][8][9][10][11][12] Thus, defining prorepair pathways associated with inflammation is a crucial step for the development of successful therapeutic strategies.Leukotrienes are short-lived lipid mediators derived from the conversion of arachidonic acid by 5-lipoxygenase and consist of leukotriene B 4 and the cysteinyl leukotrienes: leukotriene C 4 , leukotriene D 4 , and leukotriene E 4 . 13,14 [See Figure, Supplemental Digital Content 1, which shows the 5-lipoxygenase (5-LO) pathway. A variety of stimuli can induce the release of arachidonic acid from membrane phospholipids by cytosolic phospholipase A2 (cPLA2; gene name, Pla2g4a). 5-Lipoxygenase (gene name, Alox5), together with 5-lipoxygenase activating protein (FLAP; gene name, Alox5ap), converts free arachidonic acid to form the unstable intermediate leukotriene A4 (LTA4). Leukotriene A4 can be either hydrolyzed by leukotriene A4 hydrolase (LTA4H; gene name, Lta4h) to form leukotriene B4 (LTB4) or conjugated to reduced glutathione by leukotriene Background: Burns are severe injuries often associated with impaired wound healing. Impaired healing is caused by multiple factors, including dysregulated inflammatory responses at the wound site. Interestingly, montelukast, an antagonist for cysteinyl leukotrienes and U.S. Food and Drug Administration approved for treatment of asthma and allergy, was previously shown to enhance healing in excision wounds and to modulate local inflammation. Methods: In this study, the authors examined the effect of montelukast on wound healing in a mouse model of scald burn injury. Burn wound tissues isolated from montelukast-and vehicle-treated mice at various times after burn injury were analyzed for wound areas (n = 34 to 36), reepithelialization (n = 14), inflammation (n = 8 to 9), and immune cell infiltration (n = 3 to 6) and proliferation (n = 7 to 8). Results: In contrast to previously described beneficial effects in excision wounds, this study shows that montelukast delays burn wound healing by impairing the proliferation of keratinocytes and endothelial cells. This occurs largely independently of inflammatory responses at the wound site, suggesting that montelukast impairs specifically the proliferative phase of wound healing in burns. Wound healing rates in mice in which leukotrienes are not produced were not affected by montelukast. Conclusion: Montelukast delays wound healing mainly by reducing the proliferation of local cells after burn injury. (Plast. Reconstr. Surg. 150: 92e, 2022.) Clinical Relevance Statement: Al...

show abstract

Section: Discussionmentioning

confidence: 62%

Montelukast, an Antagonist of Cysteinyl Leukotriene Signaling, Impairs Burn Wound Healing

Nguyen

Bagood

Wang

et al. 2022

Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

show abstract

“…Di Salvo and coauthors conducted a review of the literature to examine the incidence of adverse skin reactions associated with use of montelukast ( Di Salvo et al, 2020 [A]). The review identified 17 case reports published between 2000 and 2014.…”

Section: Leukotriene Modifiers [Seda-36 245; Seda-37 197; Seda-38 160; Seda-39 166; Seda-40 219; Seda-41 172; Seda-42 172]mentioning

confidence: 99%

Drugs that act on the respiratory tract

Yogaratnam

Bylo

Carey

et al. 2021

Side Effects of Drugs Annual

View full text Add to dashboard Cite

“…16 Leukotriene receptor antagonists such as montelukast are used to improve symptoms of asthma and allergic rhinitis but cause cutaneous adverse effects such as rash, urticaria, and vascular water. 17 In addition, the popular allergen immunotherapy is effective, but the small number of allergens, the long treatment time, and the high cost limit its wide application. 15 All in all, a safer, more effective, and natural alternative treatment strategy is urgently needed.…”

Section: Introductionmentioning

confidence: 99%

“…GCSs can effectively improve the symptoms of rhinitis and is suitable for patients with severe allergic sinusitis, but long-term and frequent use of GCSs may be associated with moon face, dermatologic disorders, menstrual disorders, application site disorders, and hypoadrenocorticism . Leukotriene receptor antagonists such as montelukast are used to improve symptoms of asthma and allergic rhinitis but cause cutaneous adverse effects such as rash, urticaria, and vascular water . In addition, the popular allergen immunotherapy is effective, but the small number of allergens, the long treatment time, and the high cost limit its wide application .…”

Section: Introductionmentioning

confidence: 99%

A Supramolecular Assembly of EGCG for Long-Term Treatment of Allergic Rhinitis

Zhang,

Tan,

Zeng

et al. 2024

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Allergic rhinitis (AR) is a type-I hypersensitivity disease mediated by immunoglobulin E (IgE). Although antihistamines, glucocorticoids, leukotriene receptor antagonists, and other drugs are widely used to treat AR, the various adverse side effects of long-term use of these drugs should not be ignored. Therefore, more effective and safe natural alternative strategies are urgently needed. To this end, this study designed a nanosupramolecular delivery system composed of β-cyclodextrin supramolecular polymer (PCD), thiolated chitosan (TCS), and natural polyphenol epigallocatechin gallate (EGCG) for intranasal topical continuous treatment of AR. The TCS/PCD@EGCG nanocarriers exhibited an excellent performance in terms of retention and permeability in the nasal mucosa and released the vast majority of EGCG responsively in the nasal microenvironment, thus resulting in the significantly high antibacterial and antioxidant capacities. According to the in vitro model, compared with free EGCG, TCS/PCD@ EGCG inhibited mast cell activity and abnormal histamine secretion in a more long-term and sustained manner. According to the in vivo model, whether in the presence of continuous or intermittent administration, TCS/PCD@EGCG substantially inhibited the secretion of allergenic factors and inflammatory factors, mitigated the pathological changes of nasal mucosa, alleviated the symptoms of rhinitis in mice, and produced a satisfactory therapeutic effect on AR. In particular, the therapeutic effect of TCS/PCD@EGCG systems were even superior to that of budesonide during intermittent treatment. Therefore, the TCS/PCD@EGCG nanocarrier is a potential long-lasting antiallergic medicine for the treatment of AR.

show abstract

The leukotriene receptor antagonist Montelukast can induce adverse skin reactions in asthmatic patients

Cited by 7 publications

References 27 publications

Montelukast, an Antagonist of Cysteinyl Leukotriene Signaling, Impairs Burn Wound Healing

Montelukast, an Antagonist of Cysteinyl Leukotriene Signaling, Impairs Burn Wound Healing

Drugs that act on the respiratory tract

A Supramolecular Assembly of EGCG for Long-Term Treatment of Allergic Rhinitis

Contact Info

Product

Resources

About